Last reviewed · How we verify
Bimatoprost cutaneous solution 0.03%
Bimatoprost cutaneous solution 0.03% is a Prostaglandin analog Small molecule drug developed by Allergan. It is currently in Phase 2 development for Open-angle glaucoma, Ocular hypertension. Also known as: GLASH VISTA™, Latisse®.
Bimatoprost activates the prostaglandin F2 alpha receptor (FP receptor), leading to increased uveoscleral outflow of aqueous humor and reduced intraocular pressure.
Bimatoprost activates the prostaglandin F2 alpha receptor (FP receptor), leading to increased uveoscleral outflow of aqueous humor and reduced intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Bimatoprost cutaneous solution 0.03% |
|---|---|
| Also known as | GLASH VISTA™, Latisse® |
| Sponsor | Allergan |
| Drug class | Prostaglandin analog |
| Target | FP receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
Bimatoprost is a prostaglandin analog that mimics the natural ligand of the FP receptor, enhancing the outflow of aqueous humor through the uveoscleral pathway, which is a key mechanism in reducing intraocular pressure in conditions such as glaucoma.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Blurred vision
Key clinical trials
- Topical Bimatoprost in the Treatment of Migraine (PHASE2)
- Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study) (PHASE4)
- Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bimatoprost cutaneous solution 0.03% CI brief — competitive landscape report
- Bimatoprost cutaneous solution 0.03% updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about Bimatoprost cutaneous solution 0.03%
What is Bimatoprost cutaneous solution 0.03%?
How does Bimatoprost cutaneous solution 0.03% work?
What is Bimatoprost cutaneous solution 0.03% used for?
Who makes Bimatoprost cutaneous solution 0.03%?
Is Bimatoprost cutaneous solution 0.03% also known as anything else?
What drug class is Bimatoprost cutaneous solution 0.03% in?
What development phase is Bimatoprost cutaneous solution 0.03% in?
What are the side effects of Bimatoprost cutaneous solution 0.03%?
What does Bimatoprost cutaneous solution 0.03% target?
Related
- Drug class: All Prostaglandin analog drugs
- Target: All drugs targeting FP receptor
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
- Also known as: GLASH VISTA™, Latisse®
- Compare: Bimatoprost cutaneous solution 0.03% vs similar drugs
- Pricing: Bimatoprost cutaneous solution 0.03% cost, discount & access